Catabasis Pharmaceuticals to Present the Design of MoveDMD, a Phase 1/2 Trial for its Product Candidate CAT-1004 for the Treatment of Duchenne Muscular Dystrophy, at Parent Project Muscular Dystrophyâs Annual Connect Confe